MErCuRIC1: A phase 1a study of MEK1/2 inhibitor PD-0325901 with cMET inhibitor crizotinib in patients with advanced solid tumours
Autoři
WILSON, R; MR MIDDLETON; J HOULDEN; Schaeybroeck S VAN; CD ROLFO; E ELEZ; J TAIEB; T ANDRE; A BARDELLI; P LAURENT-PUIG; J TABERNERO; M PEETERS; T MAUGHAN; C ROBERTS; S LOVE; M LAWLER; M SALTO-TELLEZ; M GRAYSON; Vlad POPOVICI a Nicolantonio F DI
WILSON, R; MR MIDDLETON; J HOULDEN; Schaeybroeck S VAN; CD ROLFO; E ELEZ; J TAIEB; T ANDRE; A BARDELLI; P LAURENT-PUIG; J TABERNERO; M PEETERS; T MAUGHAN; C ROBERTS; S LOVE; M LAWLER; M SALTO-TELLEZ; M GRAYSON; Vlad POPOVICI a Nicolantonio F DI. MErCuRIC1: A phase 1a study of MEK1/2 inhibitor PD-0325901 with cMET inhibitor crizotinib in patients with advanced solid tumours. 2016. Dostupné z: https://doi.org/10.1093/annonc/mdw370.28.
@proceedings{1392209, author = {Wilson, R and Middleton, MR and Houlden, J and Van, Schaeybroeck S and Rolfo, CD and Elez, E and Taieb, J and Andre, T and Bardelli, A and LaurentandPuig, P and Tabernero, J and Peeters, M and Maughan, T and Roberts, C and Love, S and Lawler, M and SaltoandTellez, M and Grayson, M and Popovici, Vlad and Di, Nicolantonio F}, doi = {https://doi.org/10.1093/annonc/mdw370.28}, language = {eng}, title = {MErCuRIC1: A phase 1a study of MEK1/2 inhibitor PD-0325901 with cMET inhibitor crizotinib in patients with advanced solid tumours}, url = {http://dx.doi.org/10.1093/annonc/mdw370.28}, year = {2016} }
TY - CONF ID - 1392209 AU - Wilson, R - Middleton, MR - Houlden, J - Van, Schaeybroeck S - Rolfo, CD - Elez, E - Taieb, J - Andre, T - Bardelli, A - Laurent-Puig, P - Tabernero, J - Peeters, M - Maughan, T - Roberts, C - Love, S - Lawler, M - Salto-Tellez, M - Grayson, M - Popovici, Vlad - Di, Nicolantonio F PY - 2016 TI - MErCuRIC1: A phase 1a study of MEK1/2 inhibitor PD-0325901 with cMET inhibitor crizotinib in patients with advanced solid tumours UR - http://dx.doi.org/10.1093/annonc/mdw370.28 L2 - http://dx.doi.org/10.1093/annonc/mdw370.28 ER -
WILSON, R; MR MIDDLETON; J HOULDEN; Schaeybroeck S VAN; CD ROLFO; E ELEZ; J TAIEB; T ANDRE; A BARDELLI; P LAURENT-PUIG; J TABERNERO; M PEETERS; T MAUGHAN; C ROBERTS; S LOVE; M LAWLER; M SALTO-TELLEZ; M GRAYSON; Vlad POPOVICI a Nicolantonio F DI. \textit{MErCuRIC1: A phase 1a study of MEK1/2 inhibitor PD-0325901 with cMET inhibitor crizotinib in patients with advanced solid tumours}. 2016. Dostupné z: https://doi.org/10.1093/annonc/mdw370.28.